Another PerkinElmer diagnostic product available in this country is the AutoDELFIA C-peptide Kit for the quantitative determination of C-peptide in serum and heparin plasma. This assay is used to assess the residual -cell function in patients treated with insulin, to distinguish between type 1 and type 2 diabetes, and various other diagnostic applications in patients with abnormal insulin secretion. The analytical sensitivity of the assay is typically better than 0.015 ng/mL (4.97 pmol/L).
Definition of chromosome anomalies in prenatal, postnatal and preimplantation genetics is sometimes critical for predicting pregnancy outcome and future quality of life. Vysis, Inc., Downers Grove, Ill., a division of Abbott Laboratories, has gained FDA approval for its Aneuvysion assay, the only FDA cleared product to test for prenatal aneuploidy. Vysis offers an expansive line of DNA FISH (fluorescence in situ hybridization) probes for evaluation of chromosome anomalies in preimplantation, prenatal and postnatal genetic testing and research.
The availability of genetic analysis tools for mainstream clinical use offers exciting new prospects for timely, accurate diagnostic, screening and evaluative tasks. Paradoxically, in this realm of genetic analysis, as in so many other aspects of modern medicine, the more sophisticated biomedical technology becomes, the greater its accessibility, breadth of application and affordability.